Ignite Creation Date:
2025-12-18 @ 8:12 AM
Ignite Modification Date:
2025-12-23 @ 10:51 PM
Study NCT ID:
NCT02048124
Status:
None
Last Update Posted:
2020-11-10 00:00:00
First Post:
2014-01-09 00:00:00
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Study Comparing 25d ProCor Needle Versus the Standard 25g Needle for Biopsies Performed by EUS-FNA
Sponsor:
None
Organization:
Study Overview
Official Title:
Prospective Study Comparing the Diagnostic Yield of Solid Lesion Biopsies Performed by EUS-FNA Using the 25d ProCor Needle Versus the Standard 25g Needle.
Status:
None
Status Verified Date:
2020-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Objectives of the study
The primary objective is to compare the diagnostic yield of biopsies performed by EUS-FNA using the 25d ProCor needle versus the standard 25g needle.
The primary outcome is the diagnostic yield defined as: sensitivity for the presence of cancer based on the analysis of EUS-FNA samples.
The secondary objectives are:
1. to compare the size of the "core" samples produced by the two types of needles.
2. to compare the incidence and severity of immediate complications associated with the two types of needles
Methods
Design: This a prospective clinical study for the validation of a new instrument (ProCor biopsy needle) for application to clinical medicine, namely the diagnosis of cancer.
Endoscopic procedures:
Informed consent by the patient will be obtained before each procedure by a single research assistant.
All EUS examinations will be performed under conscious sedation (midazolam, fentanyl) by one two experienced endosonographers according to the standard procedures at the CHUM and using a linear echoendoscope. , If the lesion is considered solid and EUS-FNA is considered clinically indicated and safe, the patient will be enrolled and the randomisation envelope will be opened. EUS-FNA Biopsies will be obtained with both the 25S and 25P needles in each lesion; a randomisation sequence will set in order to determine which of the two needles will first be used (25S or 25P).
EUS-FNA passes will be performed without stylet. One "needle pass" is defined as 5 strokes in 4 different areas of the lesion. The material from the first 2 needle passes (one 25S and the other 25P) will be expressed into formalin to look for core samples. Material from the next 2 needle passes (again one 25S and the other 25P) will be expressed onto slides for cytological analysis. Ease of puncture will be scored qualitatively as poor (scored 1), good (scored 2) or excellent (scored 3).
Immediate complications will be assessed and recorded by nurses and/or physicians during the procedure as well after the procedure while the patients will be monitored in the recovery room for at least 60 minutes before discharge.
The areas which will be investigated by biopsy will be the pancreas, the retroperitoneal and/or the mediastinal lymph nodes.
Cytological and Histological analyses:
Samples from all needle passes will be stained using a standard Papanicolaou stain and analyzed by one experienced pathologist who will be blinded as to needle type. The cytological or histological diagnoses will be made; . for histological diagnosis, the pathologist will first establish the presence or absence of a tissue core (defined as a measurable cylinder of tissue). The pathologist will assess the adequacy of each specimen: cellularity (score 1 "poor"; score 2 "good"; score 3 "excellent"),\[14\] sample bloodiness (score 1 "minimal";score 2 "moderate"; score 3 "significant", and the presence or absence of malignancy("positive" / "negative" / "suspicious" / inconclusive).
Diagnostic yield Diagnostic yield is defined as sensitivity for the presence of cancer based on the analysis of EUS-FNA samples. The gold standard will be the presence of cancer as defined on the basis of at least one of the following two criteria: positive cytological or histological results and malignant disease after clinical follow up (clinical worsening and radiologic evidence of progression within the 6 months following FNA).
Data collection
Clinical data will be collected prospectively and saved in a database. In addition to demographics, these will include:
* size and location (pancreas, lymph node, liver, adrenal gland, others) of the target lesion
* technical and procedure variables ( FNA path, , number of needle passes, needle visibility, ease to puncture, needle failure, cellularity, bloodiness)
* cytological diagnosis
* final diagnosis
* immediate complications. Research data and project-related documents will be preserved during 15 year after the end of the study.
Statistical analysis Results for continuous variables will be summarized using mean ± (Standard Deviation) SD, . and categorical variables using proportions. The 25S and 25P groups will be compared using Chi-square test for categorical variables and, Student t test for continuous variablesTwo-sided p values less than 0.05 will be considered statistically significant. Data will be analyzed using SPSS v 15.0 (SPSS Inc., Chicago IL) statistical software.
Sample size The sample size is calculated as a study of non-inferiority. Assuming a sensitivity for cancer of 85% for the 25S needle and a difference of sensitivity of 15% as clinically significant, a sample size of 112 patients per group would be needed (α = 0.05 and β = 0.2). Since we perform approximately 400 EUS-FNA biopsies for solid lesions annually,. it is expected that this study could be completed within approximately 6 months.
The primary objective is to compare the diagnostic yield of biopsies performed by EUS-FNA using the 25d ProCor needle versus the standard 25g needle.
The primary outcome is the diagnostic yield defined as: sensitivity for the presence of cancer based on the analysis of EUS-FNA samples.
The secondary objectives are:
1. to compare the size of the "core" samples produced by the two types of needles.
2. to compare the incidence and severity of immediate complications associated with the two types of needles
Methods
Design: This a prospective clinical study for the validation of a new instrument (ProCor biopsy needle) for application to clinical medicine, namely the diagnosis of cancer.
Endoscopic procedures:
Informed consent by the patient will be obtained before each procedure by a single research assistant.
All EUS examinations will be performed under conscious sedation (midazolam, fentanyl) by one two experienced endosonographers according to the standard procedures at the CHUM and using a linear echoendoscope. , If the lesion is considered solid and EUS-FNA is considered clinically indicated and safe, the patient will be enrolled and the randomisation envelope will be opened. EUS-FNA Biopsies will be obtained with both the 25S and 25P needles in each lesion; a randomisation sequence will set in order to determine which of the two needles will first be used (25S or 25P).
EUS-FNA passes will be performed without stylet. One "needle pass" is defined as 5 strokes in 4 different areas of the lesion. The material from the first 2 needle passes (one 25S and the other 25P) will be expressed into formalin to look for core samples. Material from the next 2 needle passes (again one 25S and the other 25P) will be expressed onto slides for cytological analysis. Ease of puncture will be scored qualitatively as poor (scored 1), good (scored 2) or excellent (scored 3).
Immediate complications will be assessed and recorded by nurses and/or physicians during the procedure as well after the procedure while the patients will be monitored in the recovery room for at least 60 minutes before discharge.
The areas which will be investigated by biopsy will be the pancreas, the retroperitoneal and/or the mediastinal lymph nodes.
Cytological and Histological analyses:
Samples from all needle passes will be stained using a standard Papanicolaou stain and analyzed by one experienced pathologist who will be blinded as to needle type. The cytological or histological diagnoses will be made; . for histological diagnosis, the pathologist will first establish the presence or absence of a tissue core (defined as a measurable cylinder of tissue). The pathologist will assess the adequacy of each specimen: cellularity (score 1 "poor"; score 2 "good"; score 3 "excellent"),\[14\] sample bloodiness (score 1 "minimal";score 2 "moderate"; score 3 "significant", and the presence or absence of malignancy("positive" / "negative" / "suspicious" / inconclusive).
Diagnostic yield Diagnostic yield is defined as sensitivity for the presence of cancer based on the analysis of EUS-FNA samples. The gold standard will be the presence of cancer as defined on the basis of at least one of the following two criteria: positive cytological or histological results and malignant disease after clinical follow up (clinical worsening and radiologic evidence of progression within the 6 months following FNA).
Data collection
Clinical data will be collected prospectively and saved in a database. In addition to demographics, these will include:
* size and location (pancreas, lymph node, liver, adrenal gland, others) of the target lesion
* technical and procedure variables ( FNA path, , number of needle passes, needle visibility, ease to puncture, needle failure, cellularity, bloodiness)
* cytological diagnosis
* final diagnosis
* immediate complications. Research data and project-related documents will be preserved during 15 year after the end of the study.
Statistical analysis Results for continuous variables will be summarized using mean ± (Standard Deviation) SD, . and categorical variables using proportions. The 25S and 25P groups will be compared using Chi-square test for categorical variables and, Student t test for continuous variablesTwo-sided p values less than 0.05 will be considered statistically significant. Data will be analyzed using SPSS v 15.0 (SPSS Inc., Chicago IL) statistical software.
Sample size The sample size is calculated as a study of non-inferiority. Assuming a sensitivity for cancer of 85% for the 25S needle and a difference of sensitivity of 15% as clinically significant, a sample size of 112 patients per group would be needed (α = 0.05 and β = 0.2). Since we perform approximately 400 EUS-FNA biopsies for solid lesions annually,. it is expected that this study could be completed within approximately 6 months.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: